The report must give a timeline for labeling changes and other possible actions
What the document says“a timeline for an assessment of the potential need, as appropriate, for labeling changes, revised or additional postmarketing requirements, enforcement actions, or withdrawals for opioid analgesic drugs”
The section lists four contents for the report: an update on actions the FDA has taken on the effectiveness, safety, benefit and risk profile and use of approved opioid analgesic drugs; a timeline for assessing possible labeling changes, postmarketing requirements, enforcement actions or withdrawals; an overview of steps taken to support nonaddictive products; and an overview of the agency's consideration of clinical trial methods.
What the document actually says“a timeline for an assessment of the potential need, as appropriate, for labeling changes, revised or additional postmarketing requirements, enforcement actions, or withdrawals for opioid analgesic drugs”
The report must set out a schedule. The schedule covers checks on what may need to change. Labels, extra safety studies, or even pulling a drug are all on that list.
A postmarket study is done after a drug goes on sale. Withdrawal means pulling a drug off the market. The report only sets a schedule for looking at these.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.